基于多重平行打击学说的柴胡活性成分干预代谢相关脂肪性肝病的研究进展OA
Research progress on intervention of active components of Bupleuri Radix in metabolic dysfunction-associated fatty liver disease based on multiple parallel strike theory
代谢相关脂肪性肝病(MAFLD)是全球高发的慢性肝病,受限于复杂的发病机制,现阶段临床尚无能针对其病理全程干预的特效药及统一、确切的治疗方案.在中医学中,MAFLD 归属于"胁痛""肝癖"等疾病范畴,核心病机为"肝经郁滞、气行不畅",而柴胡"疏肝解郁、通利气机"的药性特点与其高度契合.同时数据挖掘研究显示,柴胡在中医药治疗 MAFLD 的临床方案中使用率位居前列,其药对及经典复方在临床应用中展现出良好的治疗效果.现代药理学研究也证实,柴胡含有丰富的活性成分,主要包括皂苷类如柴胡皂苷 A、D、B2 等;挥发油类如 D-柠檬烯、己酸等;黄酮类如槲皮素、芦丁、山柰酚以及柴胡多糖等.这些活性成分可针对 MAFLD"多重平行打击"的多个病理环节,如改善胰岛素抵抗(IR)、缓解内质网应激(ERS)、修复线粒体功能、调控氧化应激(OS)反应、调节肠道菌群失衡及抑制炎症小体激活,进而减缓 MAFLD 的进展.其作用机制与PI3K/Akt、PPAR、Nrf2、AMPK、MAPK、PINK1/Parkin 等信号通路,NLRP3 炎症小体及"肠-肝"轴调控密切相关,体现了中医药多成分、多靶点、多机制的整合调控优势.未来可进一步围绕柴胡的精确组分解析、关键靶点验证及"方剂-成分"协同机制等方面开展深入研究,以期更好地发挥柴胡在 MAFLD 防治中的价值.
Metabolic dysfunction-associated fatty liver disease(MAFLD)is a prevalent chronic liver disease worldwide.Due to its complex pathogenesis,there is currently no specific drug capable of intervening throughout the entire pathological process,nor a unified and definitive treatment protocol in clinical practice.In traditional Chinese medicine,MAFLD falls under the category of diseases such as"hypochondriac pain"and"liver disease",with the core pathogenesis being"stagnation of the liver meridian and obstruction of Qi movement".The pharmacological characteristics of Bupleuri Radix(BR),which"soothes the liver,relieves stagnation,and promotes Qi movement",are highly consistent with this pathogenesis.Furthermore,data mining studies have shown that BR is among the most frequently used herbs in TCM clinical protocols for treating MAFLD,and its herb pairs and classic formulas have demonstrated favorable therapeutic effects in clinical application.Modern pharmacological studies have also confirmed that BR is rich in active ingredients,including saponins(e.g.,saikosaponin A/D/B2),volatile oils(e.g.,D-limonene,hexanoic acid),flavonoids(e.g.,quercetin,rutin,kaempferol),and polysaccharides.These active ingredients can target multiple pathological aspects of the"multiple parallel hits"in MAFLD,such as improving insulin resistance(IR),alleviating endoplasmic reticulum stress(ERS),repairing mitochondrial function,regulating oxidative stress(OS)response,modulating intestinal microbiota imbalance,and inhibiting inflammasome activation,thereby slowing the progress of MAFLD.Its mechanism of action is closely related to the regulation of PI3K/Akt,PPAR,Nrf2,AMPK,MAPK,PINK1/Parkin,NLRP3 inflammasome and the"gut-liver axis",reflecting the integrative regulatory advantages of TCM's multi-component,multi-target and multi-mechanism approach.Future in-depth studies should focus on precise component profiling of BR,validation of key targets,and the synergistic mechanisms within"formula-component"interactions to better leverage the value of BR in the prevention and treatment of MAFLD.
王俊皓;苏苗;张秋菊;刘迎;陈世玉;刘文晶;曹郡薇;赵鲲鹏
甘肃中医药大学 中医临床学院,甘肃 兰州 730000甘肃中医药大学 中医临床学院,甘肃 兰州 730000甘肃中医药大学 中医临床学院,甘肃 兰州 730000甘肃中医药大学 中医临床学院,甘肃 兰州 730000甘肃中医药大学 中医临床学院,甘肃 兰州 730000甘肃中医药大学 中医临床学院,甘肃 兰州 730000甘肃中医药大学 中医临床学院,甘肃 兰州 730000甘肃中医药大学 中医临床学院,甘肃 兰州 730000
代谢相关脂肪性肝病柴胡活性成分中医药作用机制
metabolic dysfunction-associated fatty liver diseaseBupleuri Radixactive ingredientstraditional Chinese medicinemechanism of action
《中国中药杂志》 2026 (9)
2417-2427,11
国家自然科学基金项目(81660772)甘肃省中医药管理局科研课题(GZK-2018-2)甘肃中医药大学"岐黄英才"导师专项基金项目(ZYXKBD-202413)甘肃中医药大学研究生创新创业基金项目(2026CXCY-271)
评论